Cargando…
Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428469/ https://www.ncbi.nlm.nih.gov/pubmed/36059609 http://dx.doi.org/10.3389/fonc.2022.951864 |
_version_ | 1784779125923250176 |
---|---|
author | Zhou, Xuehao Ao, Xiang Jia, Zhaojun Li, Yiwen Kuang, Shouxiang Du, Chengcheng Zhang, Jinyu Wang, Jianxun Liu, Ying |
author_facet | Zhou, Xuehao Ao, Xiang Jia, Zhaojun Li, Yiwen Kuang, Shouxiang Du, Chengcheng Zhang, Jinyu Wang, Jianxun Liu, Ying |
author_sort | Zhou, Xuehao |
collection | PubMed |
description | Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively extend patient survival. However, the development of drug resistance seriously limits the clinical efficiency of chemotherapy and ultimately results in treatment failure and patient death. A large number of studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long non-coding RNAs, and circular RNAs, are widely involved in the regulation of cancer drug resistance. Their dysregulation contributes to the development of cancer drug resistance by modulating the expression of specific target genes involved in cellular apoptosis, autophagy, drug efflux, epithelial-to-mesenchymal transition (EMT), and cancer stem cells (CSCs). Moreover, some ncRNAs also possess great potential as efficient, specific biomarkers in diagnosis and prognosis as well as therapeutic targets in cancer patients. In this review, we summarize the recent findings on the emerging role and underlying mechanisms of ncRNAs involved in cancer drug resistance and focus on their clinical applications as biomarkers and therapeutic targets in cancer treatment. This information will be of great benefit to early diagnosis and prognostic assessments of cancer as well as the development of ncRNA-based therapeutic strategies for cancer patients. |
format | Online Article Text |
id | pubmed-9428469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94284692022-09-01 Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications Zhou, Xuehao Ao, Xiang Jia, Zhaojun Li, Yiwen Kuang, Shouxiang Du, Chengcheng Zhang, Jinyu Wang, Jianxun Liu, Ying Front Oncol Oncology Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively extend patient survival. However, the development of drug resistance seriously limits the clinical efficiency of chemotherapy and ultimately results in treatment failure and patient death. A large number of studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long non-coding RNAs, and circular RNAs, are widely involved in the regulation of cancer drug resistance. Their dysregulation contributes to the development of cancer drug resistance by modulating the expression of specific target genes involved in cellular apoptosis, autophagy, drug efflux, epithelial-to-mesenchymal transition (EMT), and cancer stem cells (CSCs). Moreover, some ncRNAs also possess great potential as efficient, specific biomarkers in diagnosis and prognosis as well as therapeutic targets in cancer patients. In this review, we summarize the recent findings on the emerging role and underlying mechanisms of ncRNAs involved in cancer drug resistance and focus on their clinical applications as biomarkers and therapeutic targets in cancer treatment. This information will be of great benefit to early diagnosis and prognostic assessments of cancer as well as the development of ncRNA-based therapeutic strategies for cancer patients. Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9428469/ /pubmed/36059609 http://dx.doi.org/10.3389/fonc.2022.951864 Text en Copyright © 2022 Zhou, Ao, Jia, Li, Kuang, Du, Zhang, Wang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhou, Xuehao Ao, Xiang Jia, Zhaojun Li, Yiwen Kuang, Shouxiang Du, Chengcheng Zhang, Jinyu Wang, Jianxun Liu, Ying Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications |
title | Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications |
title_full | Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications |
title_fullStr | Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications |
title_full_unstemmed | Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications |
title_short | Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications |
title_sort | non-coding rna in cancer drug resistance: underlying mechanisms and clinical applications |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428469/ https://www.ncbi.nlm.nih.gov/pubmed/36059609 http://dx.doi.org/10.3389/fonc.2022.951864 |
work_keys_str_mv | AT zhouxuehao noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications AT aoxiang noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications AT jiazhaojun noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications AT liyiwen noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications AT kuangshouxiang noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications AT duchengcheng noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications AT zhangjinyu noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications AT wangjianxun noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications AT liuying noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications |